OverviewSuggest Edit

Affinivax is a vaccine development company intended to treat various infectious diseases. The company's vaccines are based on Multiple Antigen Presenting System (MAPS) and provide protection against infectious diseases afflicting children and adults in both the developing and developed worlds.
HQCambridge, MA, US
Employee Ratings3.6
Overall CultureD

Latest Updates

Employees (est.) (Sept 2021)105(+10%)
Cybersecurity ratingAMore

Key People/Management at Affinivax

Steven Brugger

Steven Brugger

President and CEO, Director
Bob More

Bob More

Chairman of the Board
Steven Altschuler

Steven Altschuler

Stuart Chaffee

Stuart Chaffee

Chief Business Officer
Kara Bickham

Kara Bickham

Chief Medical Officer
Frank Malinoski

Frank Malinoski

Senior Vice President, Clinical Development and Regulatory Affairs
Show more

Affinivax Office Locations

Affinivax has an office in Cambridge
Cambridge, MA, US (HQ)
301 Binney St #302
Show all (1)

Affinivax Financials and Metrics

Summary Metrics

Founding Date


Affinivax total Funding

$348.5 m

Affinivax latest funding size

$226 m

Time since last funding

8 months ago

Affinivax investors

Affinivax's latest funding round in January 2021 was reported to be $226 m. In total, Affinivax has raised $348.5 m
Show all financial metrics

Affinivax Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Affinivax Online and Social Media Presence

Embed Graph

Affinivax Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

Affinivax Blogs

Affinivax Appoints Kara Bickham, MD, as Chief Medical Officer

Infectious disease clinician with experience leading the clinical development of a pneumococcal vaccine brings key skills and expertise to advance MAPS vaccine pipeline CAMBRIDGE, Mass., August 9, 2021 – Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the develop…

Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae

Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) ASP3772 has also received FDA Breakthrough Therapy Designation CAMBRIDGE, Mass, USA, and TOKYO, Japan, July 12, 2021 — Affinivax, Inc. (“Affinivax”) and Astella…

Affinivax Appoints Elizabeth Radcliffe as Chief Financial Officer

Biotech leader brings financial and planning experience across many stages of product development and company growth CAMBRIDGE, Mass., May 5, 2021 – Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multi…

Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer

Biotech leader joins executive team as company evolves vaccine pipeline and grows business  CAMBRIDGE, Mass., April 20, 2021 – Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting…

Affinivax Announces Award from CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPS™ Vaccine Candidate into Clinical Trials

Novel MAPS™ vaccine is designed to induce both a B-cell and T-cell protective immune response to multiple, highly conserved staphylococcal protein antigens CAMBRIDGE, Mass., March 9, 2021 — Affinivax, Inc. (“Affinivax”), a clinical stage biotechnology company with its novel MAPS™ technology platform…

Affinivax Announces $226 Million Series C Financing to Advance its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases

Lead pneumococcal vaccine in clinical development offers potential for broader protection than any vaccine on the market or in clinical trials today Pipeline also includes first-in-class vaccines targeting healthcare-associated infections being advanced towards clinical testing CAMBRIDGE, Mass., Jan…
Show more

Affinivax Frequently Asked Questions

  • When was Affinivax founded?

    Affinivax was founded in 2014.

  • Who are Affinivax key executives?

    Affinivax's key executives are Steven Brugger, Bob More and Steven Altschuler.

  • How many employees does Affinivax have?

    Affinivax has 105 employees.

  • Who are Affinivax competitors?

    Competitors of Affinivax include Ufovax, Truvian Sciences and Molecular Stethoscope.

  • Where is Affinivax headquarters?

    Affinivax headquarters is located at 301 Binney St #302, Cambridge.

  • Where are Affinivax offices?

    Affinivax has an office in Cambridge.

  • How many offices does Affinivax have?

    Affinivax has 1 office.